Bayer/NeoPath Automated Lung Cancer Screening Prototype Ready This Year
This article was originally published in The Gray Sheet
Executive Summary
NeoPath's collaboration with Bayer Diagnostics should result in an automated lung cancer screening assay prototype ready for clinical testing by the end of 1999, when the company's merger with AutoCyte finalizes.